Pre-malignant stages of blood cancer can sometimes be present years before symptoms of disease is evident. These states are called clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined potential (CCUS) and may be stable or develop into hematological malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The clonal expansion that cause CHIP or CCUS is driven by genetic alterations in hematopoietic stem cells. Factors that determine the risk for malignant transformation in individuals with CHIP or CCUS is largely lacking.
Our research focus on how external factors such as inflammation and stress or injury to the hematopoietic compartment cooperate with genetic alterations in the development of CHIP or CCUS.
We use a humanized model system to study clonal expansion of hematopoietic cells with genetic alterations typically found in CHIP and CCUS. Clinically relevant genetic alterations are introduced in human hematopoietic cells using CRISPR/Cas9 techniques and either studied in vitro or transplanted to xenograft mice.
Current group members
Anna Staffas, PhD
Anna Hogmalm, PhD
The origin of leukemia: genetic alterations and inflammatory factors in pre-malignant clonal hematopoiesis.
Sjovall D, Staffas A. Sem Hemtol. 2020;57:7-12.
Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice.
Staffas A, Burgos da Silva M, Slingerland AE, Lazrak A, Bare CJ, Holman CD, Docampo MD, Shono Y, Durham B, Pickard AJ, Cross JR, Stein-Thoeringer C, Velardi E, Tsai JJ, Jahn L, Jay H, Lieberman S, Smith OM, Pamer EG, Peled JU, Cohen DE, Jenq RR, van den Brink MRM. Cell Host Microbe 2018;23: 447–457.
More group Anna Staffas publications on PubMed